PI3K / Akt Signaling
| CSTコード |
包装 |
希望納入価格（円） |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1073 | 100 μg | 16,000 | |
|
GSK3-beta抗体製品一覧
| 使用目的 | |
| GSK-3β (27C10) Rabbit mAb （#9315）の反応をブロックし、抗体の反応特異性を確認するために使用 |
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using GSK-3β (27C10) Rabbit mAb #9315 in the presence of control peptide (left) or GSK-3β Blocking Peptide (right).
Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3 kinase/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in
Dictyostelium
and is a component of the Wnt signaling pathway required for
Drosophila
Xenopus
and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).
-
Welsh, G.I. et al. (1996)
Trends Cell. Biol.
6, 274-279.
-
Srivastava, A.K. and Pandey, S.K. (1998)
Mol. Cell. Biochem.
182, 135-141.
-
Cross, D.A. et al. (1995)
Nature
378, 785-789.
-
Nusse, R. (1997)
Cell
89, 321-323.
-
Diehl, J.A. et al. (1998)
Genes Dev.
12, 3499-3511.
